Thanks for sharing this interesting longitudinal review of DMARD prescriptions over a 20 year period in the US. It would certainly be interesting to compare this with usage in Europe but I doubt if there are similar large databases in use here that could be used to extract the data. I was surprised at the degree of fall off in MTX usage. I would guess that the difference in use of biosimilars may be due to insurance reimbursement rules in the US which do not encourage switching to cheaper options? It is also noteworthy that Rituximab doesn't appear on the list - it may be recorded in a different way.
Thanks for sharing this interesting longitudinal review of DMARD prescriptions over a 20 year period in the US. It would certainly be interesting to compare this with usage in Europe but I doubt if there are similar large databases in use here that could be used to extract the data. I was surprised at the degree of fall off in MTX usage. I would guess that the difference in use of biosimilars may be due to insurance reimbursement rules in the US which do not encourage switching to cheaper options? It is also noteworthy that Rituximab doesn't appear on the list - it may be recorded in a different way.